DE60009777D1 - Verbindungen zur Behandlung und Vorsorge bei Diabetes - Google Patents

Verbindungen zur Behandlung und Vorsorge bei Diabetes

Info

Publication number
DE60009777D1
DE60009777D1 DE60009777T DE60009777T DE60009777D1 DE 60009777 D1 DE60009777 D1 DE 60009777D1 DE 60009777 T DE60009777 T DE 60009777T DE 60009777 T DE60009777 T DE 60009777T DE 60009777 D1 DE60009777 D1 DE 60009777D1
Authority
DE
Germany
Prior art keywords
directed
formula
compounds
treating
pharmaceutical compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60009777T
Other languages
English (en)
Other versions
DE60009777T2 (de
Inventor
Banavara Lakshman Mylari
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Application granted granted Critical
Publication of DE60009777D1 publication Critical patent/DE60009777D1/de
Publication of DE60009777T2 publication Critical patent/DE60009777T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE60009777T 1999-04-01 2000-03-20 Verbindung für Behandlung und Vorsorge bei Diabetes Expired - Fee Related DE60009777T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12743099P 1999-04-01 1999-04-01
US127430P 1999-04-01

Publications (2)

Publication Number Publication Date
DE60009777D1 true DE60009777D1 (de) 2004-05-19
DE60009777T2 DE60009777T2 (de) 2004-08-19

Family

ID=22430072

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60009777T Expired - Fee Related DE60009777T2 (de) 1999-04-01 2000-03-20 Verbindung für Behandlung und Vorsorge bei Diabetes

Country Status (10)

Country Link
US (1) US6294538B1 (de)
EP (1) EP1041068B1 (de)
JP (1) JP3356751B2 (de)
AT (1) ATE264311T1 (de)
BR (1) BR0001526A (de)
CA (1) CA2303594C (de)
DE (1) DE60009777T2 (de)
DK (1) DK1041068T3 (de)
ES (1) ES2215570T3 (de)
PT (1) PT1041068E (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6380200B1 (en) * 1999-12-07 2002-04-30 Pfizer, Inc. Combination of aldose reductase inhibitors and selective serotonin reuptake inhibitors for the treatment of diabetic complications
CO5271699A1 (es) * 2000-01-24 2003-04-30 Pfizer Prod Inc Procedimiento para el tratamiento de cardiomiopatia utilizando inhibidores de la glucogeno fosforilasa
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
PL365927A1 (en) * 2000-11-30 2005-01-10 Pfizer Products Inc. Combination of gaba agonists and sorbitol dehydrogenase inhibitors
EE200300249A (et) * 2000-11-30 2003-10-15 Pfizer Products Inc. GABA agonistide ja aldoosreduktaasi inhibiitoritekombinatsioon
EP1247809A3 (de) 2001-03-30 2003-12-17 Pfizer Products Inc. Triazin-Verbindungen und ihre Verwendung als Hemmer der Sorbit-Dehydrogenase
OA12788A (en) * 2002-03-13 2006-07-10 Janssen Pharmaceutica Nv Piperazinyl-, piperidinyl- and morpholinyl-derivatives as novel inhibitors of histone deacetylase.
DE60321548D1 (de) * 2002-03-13 2008-07-24 Janssen Pharmaceutica Nv Carbonylamino- derivativate als neue inhibitoren von histone deacetylase
AU2003218738B2 (en) * 2002-03-13 2009-01-08 Janssen Pharmaceutica N.V. Sulfonyl-derivatives as novel inhibitors of histone deacetylase
KR20040094672A (ko) 2002-03-13 2004-11-10 얀센 파마슈티카 엔.브이. 히스톤 디아세틸라제의 신규한 저해제로서의설포닐아미노-유도체
EP1485099B1 (de) 2002-03-13 2010-07-07 Janssen Pharmaceutica N.V. Histone-deacetylase-inhibitoren
EP1743676A1 (de) 2003-11-12 2007-01-17 Phenomix Corporation Heterozyklische Borsäurederivate, Inhibitoren der Dipeptidyl-Peptidase IV
US7767828B2 (en) 2003-11-12 2010-08-03 Phenomix Corporation Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US7576121B2 (en) 2003-11-12 2009-08-18 Phenomix Corporation Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US7317109B2 (en) 2003-11-12 2008-01-08 Phenomix Corporation Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
JP2008505975A (ja) 2004-07-12 2008-02-28 フェノミックス コーポレーション 制約されたシアノ化合物
BRPI0512676B8 (pt) * 2004-07-28 2021-05-25 Janssen Pharmaceutica Nv derivados de indolil alquil amina substituídos como inibidores de histona desacetilase, composição farmacêutica que os compreende, seus processos de preparação e uso
US7214704B2 (en) 2004-11-15 2007-05-08 Bristol-Myers Squibb Company 2-Amino-1-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
WO2006055462A1 (en) 2004-11-15 2006-05-26 Bristol-Myers Squibb Company 2-amino-4-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
US7365061B2 (en) 2004-11-15 2008-04-29 Bristol-Myers Squibb Company 2-Amino-3-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
WO2006055435A1 (en) 2004-11-15 2006-05-26 Bristol-Myers Squibb Company 2-aminonaphthalene derivatives and related glycogen phosphorylase inhibitors
WO2006122926A1 (en) 2005-05-18 2006-11-23 Janssen Pharmaceutica N.V. Substituted aminopropenyl piperidine or morpholine derivatives as novel inhibitors of histone deacetylase
US7825139B2 (en) 2005-05-25 2010-11-02 Forest Laboratories Holdings Limited (BM) Compounds and methods for selective inhibition of dipeptidyl peptidase-IV
EP1981875B1 (de) * 2006-01-19 2014-04-16 Janssen Pharmaceutica N.V. Substituierte indolyl-amino-alkyl-derivate als histon-deacetylase-inhibitoren
JP5137848B2 (ja) * 2006-01-19 2013-02-06 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ヒストンデアセチラーゼのインヒビターとしてのピリジン及びピリミジン誘導体
US8114876B2 (en) * 2006-01-19 2012-02-14 Janssen Pharmaceutica N.V. Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
ES2327972T3 (es) * 2006-01-19 2009-11-05 Janssen Pharmaceutica, N.V. Derivados de aminofenil como nuevos inhibidores de histona deacetilasa.
CN105439964B (zh) * 2015-12-09 2019-02-15 河北大学 一种阿伐那非中间体的制备方法
TWI586351B (zh) * 2016-02-16 2017-06-11 長庚大學 哺乳類tor抑制劑
EP3595664A4 (de) 2017-03-17 2020-11-11 The Regents Of The University Of Colorado, A Body Corporate, A Colorado Non-Profit Indazolinhibitoren von fructokinase (khk) und verfahren zur verwendung in der behandlung von khk-vermittelten erkrankungen oder störungen
CN112618557B (zh) * 2020-11-10 2022-01-11 北京箭牧科技有限公司 瑞德西韦在制备治疗糖尿病并发症药物中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3905364A1 (de) * 1989-02-22 1990-08-23 Hoechst Ag Substituierte pyrimidin-derivate, verfahren zu ihrer herstellung und ihre verwendung als tool
DE4025387A1 (de) * 1990-08-10 1992-02-13 Hoechst Ag Substituierte pyrimidin-derivate, verfahren zu ihrer herstellung und ihre verwendung als reagenzien
JP2789134B2 (ja) 1992-09-28 1998-08-20 ファイザー・インク． 糖尿病の合併症を制御する置換ピリミジン類

Also Published As

Publication number Publication date
BR0001526A (pt) 2000-10-31
DK1041068T3 (da) 2004-05-10
JP3356751B2 (ja) 2002-12-16
JP2000297075A (ja) 2000-10-24
EP1041068B1 (de) 2004-04-14
US6294538B1 (en) 2001-09-25
DE60009777T2 (de) 2004-08-19
EP1041068A1 (de) 2000-10-04
ES2215570T3 (es) 2004-10-16
CA2303594C (en) 2004-07-06
CA2303594A1 (en) 2000-10-01
ATE264311T1 (de) 2004-04-15
PT1041068E (pt) 2004-07-30

Similar Documents

Publication Publication Date Title
DE60009777D1 (de) Verbindungen zur Behandlung und Vorsorge bei Diabetes
MY136039A (en) Sorbitol dehydrogenase inhibitors
ATE396190T1 (de) Substituierte heteroarylalkansäure und ihre verwendung als inhibitoren der aldose reductase
DE60009929D1 (de) Glucopyranosyloxypyrazol-derivate, diese enthaltende arzneimittel und zwischenprodukte zu deren herstellung
ATE369337T1 (de) Neue bizyklische verbindungen
ATE312114T1 (de) Glucopyranosyloxy-benzylbenzen-derivate, medizinische zusammensetzung und zwischenprodukte für die herstellung der derivate
WO2006012395A3 (en) Peptidase inhibitors
BR0213660A (pt) Composto, composição farmacêutica e método para tratar pacientes
PL2404901T3 (pl) 1,2-Dipodstawione pochodne 4-benzyloamino-pirolidyny jako inhibitory CETP użyteczne do leczenia chorób, takich jak hiperlipidemia lub stwardnienie tętnic
ATE337318T1 (de) Spiroverbindungen und diese als wirkstoff enthaltende adhäsionsmolekülinhibitoren
ATE160780T1 (de) Spiro-isochinolin-pyrrolidine und analoge davon zur verwendung als aldose-reduktase-hemmer
DK1562604T3 (da) Prostaglandinforbindelser til behandling af fedme
DE60227421D1 (de) Rmazeutische zusammensetzung und verwendung davon
DE602004019778D1 (de) Verwendung von 2-amino-1,3-propandiolderivaten zur herstellung eines medikaments zur behandlung von bestimmten schmerzen
DE60204611D1 (de) Sulfonyl-pyridazinon-derivate zur verwendung als aldose-reduktase-inhibitoren
IL147348A0 (en) Tricyclic compounds having spiro union
ATE279182T1 (de) Verwendung spezieller verbindungen zur prophylaxe und therapie von hepatitis c
WO2005025492A3 (en) Novel compositions, pharmaceutical compositions, and methods for the treatment and prevention of heart disease
TH70058A (th) อนุพันธ์ 2, 3 -ไดแอริล-ไพราโซลิดีนชนิดใหม่ที่เป็นตัวยับยั้งเอนไซม์ที่ทำให้นิวโรเทนซินเสื่อมสลาย
TH68659A (th) อนุพันธ์อะนิลิโนไพราโซลที่มีประโยชน์สำหรับการบำบัดโรคเบาหวาน
TH71270A (th) สารยับยั้งเบตา-อะมิโนเฮเทอโรไซคลิกไดเปปติดิลเปปติเดสสำหรับการบำบัดหรือการป้องกันโรคเบาหวาน
TH88286A (th) สารยับยั้งสไปโรพิเพอริดินเบตา-ซีเครเตสสำหรับการรักษาของโรคแอลไซเมอร์

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee